Indirect medical costs in the first 3 years of rheumatoid arthritis: comparison of current methodological approaches

References

• McIntosh E. The cost of rheumatoid arthritis. Br. Rheumatol. 35 (8), 781–790 (1996).
   Google Scholar
• Clarke AE, Zowall H, Levinton C et al Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J. Rheumatol. 24, 1051–1060 (1997).
   Google Scholar
• ••Provides original data about productivity loss and indirect costs in RA.
   Google Scholar
• Yelin EH. The cost of rheumatoid arthritis: absolute, incremental, and marginal estimates. J. Rheumatol. 44(Suppl.), 47–51 (1996).
   Google Scholar
• Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum. 21, 827–833 (1978).
   PubMedGoogle Scholar
• Gabriel SE, Crowson CS, Luthra HS, Wagner JL, O'Fallon WM. Modeling the lifetime costs of rhematoid arthritis. J. Rheumatol. 26,1269–1274 (1999).
   Google Scholar
• Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 42, 1209–1218 (1999).
   PubMed Web of Science ®Google Scholar
• Newhall-Perry K, Law NJ, Ramos B et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. j Rheumatol. 27:1156–1163 (2000).
   PubMedGoogle Scholar
• ••Provides original data about productivity loss and indirect costs in RA, including productivity losses by unpaid work.
   Google Scholar
• Kobelt G, Jonsson L, Mattiasson A. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis .Rheum. 42,347–356 (1999).
   PubMed Web of Science ®Google Scholar
• Yelin EH. Musculoskeletal conditions and employment. Arthritis Care Res. 8,311–317 (1995).
   PubMedGoogle Scholar
• Anis AH, Tugwell PX, Wells GA, Stewart DG. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. J. Rheumatol. 23, 609–616 (1996). itChoi HK, Seeger JD, Kuntz KM. A cost- effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum. 43, 2316–2327 (2000).
   Google Scholar
• Brennan A, Bansback N, Conway P, Reynolds AV Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis (RA) in the UK. Arthritis Rheum. 44\(Suppl. 9), 157 (2001).
   Google Scholar
• Kobelt G, Jonsson L, Lindquist E, Eberhardt Speracedes K. Cost-effectiveness of Infliximab (Remicade) in Sweden. Arthritis Rheum. 44\(Suppl. 9), 158 (2001).
   Google Scholar
• ••Shows the impact of the inclusion ofindirect costs in CEAs on the CE ratios.
   Google Scholar
• Merkesdal S, Ruof J, Mittendorf T, Mau W, Zeidler H. [Health economic research in rheumatoid arthritis]. Z Rheumatol 61, 21–29 (2002).
   Google Scholar
• Ruff B. OMERACT: economic evaluations and health policy. J. Rheumatol. 26, 2076–2077(1999).
   Google Scholar
• Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J. Rheumatol 24, 43–48 (1997).
   Google Scholar
• Magnusson S. Treatment of rheumatoid arthritis - does it affect society's cost for the disease? BE jRheumatol. 35, 791–795 (1996).
   Google Scholar
• •• Provides original data about productivity loss and indirect costs in RA.
   Google Scholar
• Merkesdal S, Ruof J, Schoeffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum. 44, 528–534 (2001).
   PubMed Web of Science ®Google Scholar
• ••Provides original data about productivity loss and indirect costs in RA.
   Google Scholar
• Merkesdal S, Ruof J, Huelsemann JL et al Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. Rheumatol. 28, 657–661 (2001).
   Google Scholar
• •Review current standardization approaches in RA economic analyses.
   Google Scholar
• Ruof J, Merkesdal S, Huelsemann JL etal. Cost assessment instrument in rheumatology: evaluation of applied instrument characteristics. J. Rheumatol 28, 662–665 (2001).
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA et al The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315–324 (1988).
   PubMed Web of Science ®Google Scholar
• Hannoveraner Konsensus Gruppe. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation — Revidierte Fassung des Hannoveraner Konsens. Cesundheitsoekonomie uncl Qualitaetsmanagement 4, A62—A65(1999). Comments on the current recommendations for assessment of productivity losses in Germany.
   Google Scholar
• Koopmanschap MA. Complementary analyses in economic evaluation of health care. Diss., Rotterdam, The Netherlands (1994).
   Google Scholar
• ••Outlines the methodological differences ofHC and FC methods.
   Google Scholar
• Statistisches Bundesamt. Statistical Yearbook 1996 for the Federal Republic of Germany. Metzler Poeschel, Wiesbaden, Germany (1996)
   Google Scholar
• Bundesanstalt fuer Arbeit: Strukturanalyse 1993, Nurnberg, Germany (1994).
   Google Scholar
• Schoeffski O, Glaser P, Schulenburg JM, Graf VD. [Health Economic Evaluation]. Springer-Verlag Berlin, Heidelberg, Germany (1998).
   Google Scholar
• •Summarizes important methodological issues surrounding cost components and assessment methods.
   Google Scholar
• Allaire SH, Anderson JJ, Meenan RE Reducing work disability associated with rheumatoid arthritis: identification of additional risk factors and persons likely to benefit from intervention. Arthritis Care Res. 9, 349–357 (1996).
   PubMedGoogle Scholar
• Eberhardt K, Larsson BM, Nived K. Early rheumatoid arthritis - some social, economical, and psychological aspects. Scand. I Rheumatol 22, 119–123 (1993).
   Google Scholar
• Mau W Bornmann M, Weber H, Weidemann HF, Hecker H, Raspe HH. Prediction of permanent work disability in a follow-up study of early rheumatoid arthritis: results of a tree structured analysis using recpam. BE J. Rheumatol 35, 652–659 (1996).
   Google Scholar
• Cost-Effectiveness in health and medicine. Gold MR et al (Eds) Oxford University Press, Inc., Oxford, UK (1996).
   Google Scholar
• •Recommendation about assessment of cost-effectiveness.
   Google Scholar
• Yelin E, Katz P, Lubeck D, Wanke L, Buatti M. Impact of etanercept (ENBREL) on health care use and employment in early RA. Arthritis Rheum. 44\(Suppl. 9), 152 (2001).
   Google Scholar
• ••Original data on economic effectiveness ofTNF-a blocking drugs
   Google Scholar
• Gabriel SE, Tugwell P, O'Brien B. Report of the OMERACT Task Force on Economic Evaluation. J. Rheumatol 26, 203–206 (1999).
   Google Scholar